One of America's biggest companies is imploding
UnitedHealth Group, one of America's biggest corporations and a member of the exclusive Dow Jones Industrial Average, is suddenly unraveling.
The crisis engulfing UnitedHealth hit a crescendo this week when CEO Andrew Witty stepped down abruptly for 'personal reasons.'
UnitedHealth also swiftly abandoned its financial guidance, blaming skyrocketing medical costs.
And then The Wall Street Journal dropped the hammer, revealing that UnitedHealth is under federal criminal investigation for possible Medicare fraud.
The developments have stunned investors, triggering a dramatic loss of confidence. UnitedHealth's (UNH) stock has lost half its value – a staggering $288 billion – in the span of a month. Its share price plunged on Thursday to its lowest level since April 2020, during the height of the pandemic.
It's a spectacular reversal of fortunes for one of America's most powerful companies and the nation's largest health insurer.
The trouble at UnitedHealth comes almost exactly six months after the murder of Brian Thompson, one of its top executives. The brazen shooting of Thompson, in Midtown Manhattan, captured international attention and surfaced deep public resentment toward the healthcare industry.
The UnitedHealth selloff gathered steam on Thursday, with the Journal report of a federal criminal investigation driving UnitedHealth shares down another 13%, leaving them on track for their worst week since 1998, according to FactSet data.
The DOJ's healthcare-fraud unit is overseeing an investigation into possible Medicare fraud at UnitedHealth, the Journal reported.
UnitedHealth responded to the report by posting a statement online that described the Journal's reporting as 'deeply irresponsible' because the paper acknowledged the precise nature of the potential criminal allegations is unclear.
'We have not been notified by the Department of Justice of the supposed criminal investigation reported, without official attribution, in the Wall Street Journal today,' UnitedHealth said in the statement. 'We stand by the integrity of our Medicare Advantage program.'
The DOJ declined to comment.
Jeffrey Sonnenfeld, founder of the Yale Chief Executive Leadership Institute, said the abrupt nature of the CEO transition at UnitedHealth is quite telling.
'The fact the board moved with this much speed means they obviously lost confidence in the CEO. It's got to be pretty bad if they moved this fast,' Sonnenfeld said. 'It's astounding.'
UnitedHealth described the CEO switch as a decision Witty made 'for personal reasons' and the company said he has agreed to serve as a senior adviser. But Sonnenfeld suspects Witty was forced out.
''Personal reasons' is the humiliation of this implosion,' he said.
UnitedHealth is turning to a familiar face to clean up the mess: Stephen Hemsley, its former longtime CEO and current chairman.
Hemsley praised Witty for displaying 'real integrity and compassion during one of the most difficult periods any company could endure.'
The new CEO also, however, made clear his displeasure with UnitedHealth's stumbles.
'To all stakeholders, including employees and shareholders, I am deeply disappointed in and apologize for the performance setbacks we have encountered from both external and internal challenges,' Hemsley said during a conference call on Tuesday.
Sonnenfeld hailed the decision by UnitedHealth's board to bring back Hemsley, who led the company to success between 2006 and 2017.
'He does know where the bodies are buried, and he's the perfect guy to go to,' he said.
Morgan Stanley analyst Erin Wright agrees, describing Hemsley in a research report as 'the most appropriate person to step in as CEO at this juncture in light of the recent setbacks.'
UBS analyst AJ Rice, in a report to clients, praised Hemsley as a 'steady hand to lead the company in this turbulent time.'
Hemsley will have his work cut out for him.
Beyond the reported DOJ investigation, UnitedHealth is facing intense scrutiny from multiple parts of the federal government.
In its annual report, UnitedHealth acknowledged the company 'has been involved or is currently involved in various governmental investigations, audits and reviews.'
UnitedHealth said these include 'routine, regular and special investigations, audits and reviews' by a wide range of agencies, including the DOJ, the Internal Revenue Service, the Labor Department and the Securities and Exchange Commission.
The developments have unnerved investors – especially the decision to abandon 2025 financial guidance.
Bank of America downgraded UnitedHealth from 'buy' to 'neutral' on Tuesday, warning that it could take years for the company to recover.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Trump's first term shows why markets are cautious on the China trade deal
The stock market was largely unmoved by the trade agreement the US struck with China. Market pros say investors expect the trade war to unfold much as it did during Trump's first term. The US and China made scant progress on key issues in their 2018-2019 trade dispute. The stock market has been encouraged by easing tensions between the US and China in recent weeks, but investors were largely unmoved by the announcement of a trade deal between the superpowers on Tuesday. US stock futures failed to climb on news of the deal late Tuesday evening. While markets are edging higher on Wednesday, that's largely because the consumer price index report for May showed inflation was tamer than expected at 2.4% year-over-year. Here's where major indexes stood at 10:20 a.m. ET: S&P 500: 6,055.26, up 0.28% Dow Jones Industrial Average: 42,997.65, up 0.31% (+130.78 points) Nasdaq Composite: 19,788.36, up 0.37% On the trade front, observers say it's looking more likely that the trade war will shake out like it did during President Donald Trump's first term, with talk of constructive deals even as tensions remain elevated. Simply put, investors see a long and winding path ahead, and knee-jerk reactions to trade announcements have largely subsided since the chaos of "Liberation Day" in April. The framework agreement announced on Tuesday outlines how the two nations will continue trade talks. Importantly, it involves China allowing exports of rare earth minerals, while the US eases up on restrictions for exports of advanced tech to China, like semiconductors. This embedded content is not available in your region. The reaction is far more muted than how the market reacted last month, when stocks popped after the US struck a rough framework deal with China that lowered tariffs between the nations for 90 days. Art Hogan, the chief market strategist at B. Riley Wealth, told Business Insider that markets are reacting to trade talks similarly to when the US-China trade war first kicked off in 2018. He pointed to regular pullbacks in stocks during Trump's first term as traders digested the lack of progress in US-China negotiations. "We still have that muscle memory from Trump 1.0, that dealing with China is difficult and there's a multitude of issues," Hogan said. "I don't think we're going to solve this in short order and likely never solve it in the longer term." He added that markets are likely waiting for a more positive catalyst, pointing to more than 100 nations that have yet to strike a trade deal with the US. Peter Berezin, the chief global strategist at BCA Research, said the framework made only small progress on negotiations with China. "I would say that the 'deal' in London simply restores things to how they were right after Geneva," he told BI in an email. He added that he expected tariffs on China to remain high "for the foreseeable future." Strategists at Deutsche Bank also said that tariff talks appear to mirror the 2018-2019 period, when the US and China didn't make much headway in resolving key issues. Back then, the US said that China had unfair trade practices related to industries like agriculture and manufacturing. It also said China had unfairly transferred technology and stolen intellectual property from the US. Deutsche Bank pointed out that the agreement announced Tuesday skipped over fentanyl-related tariffs that Trump implemented against China earlier this year. "So while the mood music has stayed positive, investors may be wary of the pattern that emerged during the previous US-China trade talks in 2018-19," strategists wrote. "So there's perhaps a little disappointment this morning that we haven't yet got a bigger announcement." The agreement also appeared to lack detail that markets were looking for, David Morrison, a senior market analyst at Trade Nation, wrote in a note. "The big question is what kind of trade deals can the US negotiate that will be good enough to get the indices to fresh records?" he said. US stocks have whipsawed this year amid the turmoil surrounding tariffs and incremental news of trade agreements between the US and other countries. Indexes have erased their steep losses since the April 2 tariff announcements, with major averages now positive year-to-date. Read the original article on Business Insider
CNBC
24 minutes ago
- CNBC
Stock futures are little changed after S&P 500 ends three-day win streak: Live updates
Traders wait for Voyager Technologies to begin trading during the company's IPO at the New York Stock Exchange (NYSE) in New York City, U.S., June 11, 2025. Brendan McDermid | Reuters Stock futures were relatively unchanged on Wednesday after the S&P 500 saw its first negative session in four. S&P 500 futures traded down by 0.1%, along with Nasdaq 100 futures . Futures tied to the Dow Jones Industrial Average dropped 44 points, or 0.1%. In extended trading, shares of Oracle surged more than 7% after its fiscal fourth-quarter results beat on the top and bottom lines. The company also indicated more cloud growth ahead, saying in a statement that cloud infrastructure revenue will rise by more than 70% in fiscal 2026, up from a 50% growth rate in the prior fiscal year. Wednesday marked a losing session on Wall Street, with the S&P 500 snapping its three-day win streak, as did the Nasdaq Composite . But the moves were slight. The broad market index fell about 0.3%, while tech-heavy Nasdaq dropped 0.5%. The Dow Jones Industrial Average was flat. While the day's losses put the S&P 500 a bit further away from reaching a new record high, the index is also still just more than 2% below its late February record. Those moves come after consumer prices rose less than expected in May, as the consumer price index increased 0.1% for the month. That's less than the Dow Jones forecast for 0.2%. Core CPI, which excludes food and energy prices, also increased less than expected. "I don't think the market has a lot of faith that we're not going to see at least a little bit higher inflation," Scott Wren, senior global market strategist at Wells Fargo, told CNBC's "Closing Bell" Wednesday. "With all the things going on, the economy slowing, earnings growth likely to slow, lots of trade negotiations to still work through, is there really a good reason to take a run at the record high? I don't know about that. It makes a lot of sense to me that we'd be choppy and maybe see a little downside here." Investors are now looking ahead to May's reading of the producer price index, due out at 8:30 a.m. ET on Thursday. Economists polled by Dow Jones are expecting the index to show a gain of 0.2% for the period. Subtracting out food and energy, core PPI is expected to show growth of 0.3% on the month. The Street is also waiting for more developments on trade, especially between the U.S. and China, as talks between the two countries have been a focal point this week. While officials reached an agreement in London, the deal still awaits approval from U.S. President Donald Trump and Chinese President Xi Jinping. Trump said in a post on Truth Social earlier Wednesday that "WE ARE GETTING A TOTAL OF 55% TARIFFS, CHINA IS GETTING 10%." However, Commerce Secretary Howard Lutnick later said that U.S. levies on goods from China won't change from their current levels. Rising tensions between the U.S. and Iran will also be in focus. U.S. crude oil futures jumped more than 4% on Wednesday after Trump expressed doubt that the two countries could reach a nuclear deal.
Yahoo
43 minutes ago
- Yahoo
Opinion - We're cancer doctors. Here's why Medicare Advantage fails America's elderly.
'It's nothing,' Tom, a retired firefighter from rural Texas, thought when he had persistent stomach pain. After shedding 30 pounds in three weeks, his family physician ordered a CT scan. Tom was not concerned — after all, the 65-year-old had gotten Medicare Advantage earlier that year. Like millions, Tom switched his insurance after he was solicited by a broker who promised low premiums and a gift card. Absent from the sales pitch was the fact that Medicare Advantage plans — privately run and separate from government-funded traditional Medicare — often delay and deny coverage. One of us met Tom nearly three months after his CT scan, and his doctor discovered the abdominal mass. The job as the first oncologist he had been able to see after months of jumping through hoops was to get initial scans, identify an in-network provider, wait for further referral and approval processes and finally schedule and complete a biopsy. The delays became a death knell. Tom was diagnosed with Stage 3 pancreatic cancer. Tom's first question was, 'It's going to be fine, right?' Despite the urge to reassure him, Tom's life and treatment options were not up to a doctor. They were up to his insurance. The same insurance that delayed urgent testing and care. By definition, Medicare Advantage is meant to support elderly medical care and increase efficiencies; in function, it is a business model that allows the American government to decrease its liability for sick seniors. Instead of absorbing and managing costs, the responsibility is outsourced to third-party operators, such as UnitedHealth Group, Humana and CVS Health. While Medicare Advantage provides excellent coverage if you never get sick, this insurance can quickly become a precursor to medical bankruptcy if the patient develops a deadly disease, a highly probable outcome when you consider that nearly 40 percent of Americans get cancer in their lifetime. After nearly two decades of experimentation and $450 billion of taxpayer money, Medicare Advantage has proven porous in terms of corruption, fraud and abuse. Yet, 32.8 million elderly Americans (54 percent of the eligible Medicare population) are currently enrolled in Medicare Advantage. In 2023 alone, Medicare Advantage plans fully or partially denied 3.2 million prior authorization requests. No one, especially among folks facing the daily drudgery of fighting cancer, truly understands how the cogs within the insurance machine work. Few of our elderly patients fight the goliath institution, and many succumb to poorer health outcomes in their quest for lifesaving treatment. Last year, countrywide and across disease groups, 79 percent of patients who experienced a delay or denial of coverage paid out of pocket for medication at least sometimes. Unsurprisingly, more than 100 million Americans are in medical debt. Of those who appealed between 2019 and 2023, over 80 percent were approved, implying that the initial claims were valid. This game of attrition directly contradicts Medicare Advantage's promise to provide efficient, patient-centered healthcare. These denials are not just medically dangerous because they enable deadly diseases to progress unchecked. They are also emotionally erosive. Daily, we see patients shrink in the face of denials, unable to emotionally navigate the complex Medicare system and the immense pain, isolation and depression resulting from this behemoth that stands between their disease and their hope to be free of it. During one of Tom's chemo visits, with thousands of dollars worth of IVs in his veins, his skin pale and translucent, he realized he was begging his insurance at every turn to support him. Stories like Tom's reveal the truth: Medicare Advantage is unapologetically failing its elderly cancer patients. Sick American seniors deserve more than insurance coverage in name only. We advise our patients to avoid Medicare Advantage. The better choice is traditional Medicare, plus a secondary or supplemental insurance. Often, people do not enroll in supplemental insurance because they do not understand its importance, believe they will never get sick, miss the deadline for approval without a medical exam (you must do this within three months before or after your 65th birthday), or think it is too expensive. Although supplemental insurance costs nearly $500 a month (exact amounts vary based on age and income), choosing this add-on — and paying roughly $6,000 a year — is much more affordable than Medicare Advantage's yearly out-of-pocket (potentially adding up to $8,500) and fighting for approvals for basic treatment. On Medicare Advantage, Tom quickly reached his maximum yearly out-of-pocket of $8,500, but then it reset on Jan. 1. After four months of treatment, he was responsible for paying $17,000 for 16 months of care, on top of his insurance premiums, simply to receive standard care. Of course, if you are one of the fortunate few to have never experienced illness — and we hope you are — Medicare Advantage can be a cheaper option. The question is, how can we make Medicare Advantage advantageous for the vulnerable? There is a bipartisan opportunity to change the narrative around this insurance model. During his confirmation hearing as the head of the Centers for Medicare and Medicaid Services, Mehmet Oz criticized Medicare Advantage insurers for some of their practices. Strategic change — omitting out-of-pocket costs for cancer patients, curbing insurance companies' rights to deny claims submitted by doctors and speeding up the process — along with more rigorous oversight of the program are worthwhile goals the Trump administration and Congress should take on. While Democrats and Republicans disagree on many issues, we believe we can all agree that people like Tom — and the millions of other Americans enrolled in Medicare Advantage — deserve comprehensive and just care. Dr. Pramod Pinnamaneni, MD, MBA, and Dr. Nitya Thummalachetty, DrPH, are founders of the Nau Project, a start-up dedicated to helping everyday Americans navigate the complexities of our healthcare system. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
